amphetamine has been researched along with Cognitive Decline in 7 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "If amphetamine can enhance the therapeutic effects of TCT, this would provide strong support for a "PACT" treatment paradigm for schizophrenia." | 6.84 | Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. ( Alvarez, AI; Bhakta, SG; Hughes, EL; Light, GA; Rana, B; Swerdlow, NR; Talledo, J; Tarasenko, M; Vinogradov, S, 2017) |
| "If amphetamine can enhance the therapeutic effects of TCT, this would provide strong support for a "PACT" treatment paradigm for schizophrenia." | 2.84 | Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. ( Alvarez, AI; Bhakta, SG; Hughes, EL; Light, GA; Rana, B; Swerdlow, NR; Talledo, J; Tarasenko, M; Vinogradov, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Perez-Palomar, B | 1 |
| Erdozain, AM | 1 |
| Erkizia-Santamaría, I | 1 |
| Ortega, JE | 1 |
| Meana, JJ | 1 |
| Pappas, AL | 1 |
| Bey, AL | 1 |
| Wang, X | 1 |
| Rossi, M | 1 |
| Kim, YH | 1 |
| Yan, H | 1 |
| Porkka, F | 1 |
| Duffney, LJ | 1 |
| Phillips, SM | 1 |
| Cao, X | 1 |
| Ding, JD | 1 |
| Rodriguiz, RM | 1 |
| Yin, HH | 1 |
| Weinberg, RJ | 1 |
| Ji, RR | 1 |
| Wetsel, WC | 1 |
| Jiang, YH | 1 |
| Grimm, CM | 1 |
| Aksamaz, S | 1 |
| Schulz, S | 1 |
| Teutsch, J | 1 |
| Sicinski, P | 1 |
| Liss, B | 1 |
| Kätzel, D | 1 |
| Nilsson, SRO | 1 |
| Heath, CJ | 1 |
| Takillah, S | 1 |
| Didienne, S | 1 |
| Fejgin, K | 1 |
| Nielsen, V | 1 |
| Nielsen, J | 1 |
| Saksida, LM | 1 |
| Mariani, J | 1 |
| Faure, P | 1 |
| Didriksen, M | 1 |
| Robbins, TW | 1 |
| Bussey, TJ | 1 |
| Mar, AC | 1 |
| Lappin, JM | 1 |
| Sara, GE | 1 |
| Managò, F | 1 |
| Mereu, M | 1 |
| Mastwal, S | 1 |
| Mastrogiacomo, R | 1 |
| Scheggia, D | 1 |
| Emanuele, M | 1 |
| De Luca, MA | 1 |
| Weinberger, DR | 1 |
| Wang, KH | 1 |
| Papaleo, F | 1 |
| Swerdlow, NR | 1 |
| Tarasenko, M | 1 |
| Bhakta, SG | 1 |
| Talledo, J | 1 |
| Alvarez, AI | 1 |
| Hughes, EL | 1 |
| Rana, B | 1 |
| Vinogradov, S | 1 |
| Light, GA | 1 |
1 review available for amphetamine and Cognitive Decline
| Article | Year |
|---|---|
Psychostimulant use and the brain.
Topics: Amphetamine; Amphetamine-Related Disorders; Brain; Central Nervous System Stimulants; Cocaine; Cocai | 2019 |
1 trial available for amphetamine and Cognitive Decline
| Article | Year |
|---|---|
Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients.
Topics: Adult; Amphetamine; Auditory Perception; Central Nervous System Stimulants; Cognitive Dysfunction; C | 2017 |
5 other studies available for amphetamine and Cognitive Decline
| Article | Year |
|---|---|
Maternal Immune Activation Induces Cortical Catecholaminergic Hypofunction and Cognitive Impairments in Offspring.
Topics: Amphetamine; Animals; Brain; Cognitive Dysfunction; Disease Models, Animal; Dopamine; Female; Humans | 2023 |
Deficiency of Shank2 causes mania-like behavior that responds to mood stabilizers.
Topics: Amphetamine; Anhedonia; Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Central Nervo | 2017 |
Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity.
Topics: Amino Acids; Amphetamine; Animals; Attention; Behavior, Animal; Bridged Bicyclo Compounds, Heterocyc | 2018 |
Continuous performance test impairment in a 22q11.2 microdeletion mouse model: improvement by amphetamine.
Topics: Amphetamine; Animals; Attention; Behavior, Animal; Central Nervous System Stimulants; Cognitive Dysf | 2018 |
Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine and Neurobehavioral Phenotypes Related to Schizophrenia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamine; Animals; Cognitive Dysfunct | 2016 |